Brief: Bionomics Ltd Says U.S. FDA Granted Fast Track Designation To BNC210 Development Program
01/12/2021 01:18
Dec 1 (Reuters) - Bionomics Ltd BNO.AX :
* U.S. FDA GRANTED FAST TRACK DESIGNATION TO BNC210
DEVELOPMENT
PROGRAM FOR ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER
Source text for Eikon: ID:nASX3h59tx
Further company coverage: BNO.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bionomics
See all newsBrief: Bionomics Announces Intention To Delist From The Australian Securities Exchange (ASX)
Brief: Bionomics Announces Its Intention To De-List From Australian Securities Exchange
Australia's Bionomics plunges to record low after co announces ASX delisting
Brief: Bionomics Ltd Seeks Trading Halt
Brief: Bionomics Says Alan Fisher Appointed Chair Of Board Of Directors